Bladder cancer, explained from the guidelines

Bladder cancer starts in the cells that line the inside of the bladder, the organ that stores urine. US guidelines estimated about 83,190 new cases and about 16,840 deaths in the United States in 2024. It is uncommon before age 40, the median age at diagnosis is 73, and men are affected about three times as often as women.

Doctors split bladder cancer into two very different diseases. Non-muscle-invasive bladder cancer (NMIBC) has not grown into the thick muscle wall of the bladder. The EAU notes that about 75% of patients are in this group when first diagnosed. These cancers are rarely life-threatening when treated well, but they often come back, and some can progress into the muscle. Treatment aims to remove the tumor, lower the chance of it returning, and catch any progression early.

Muscle-invasive bladder cancer (MIBC) has grown into the muscle wall and makes up about a quarter of new cases. It carries a real risk of spreading, so treatment is more intensive and usually involves a team: chemotherapy, surgery to remove the bladder, or a combination of chemotherapy and radiation that keeps the bladder. When the cancer has spread to distant organs, treatment focuses on medicines that work throughout the body.

The bladder wall has layers. The innermost lining is called the urothelium. Under it is a thin layer of connective tissue (the lamina propria), then a thick muscle layer (the muscularis propria, or detrusor muscle), and finally fat on the outside. How deep a tumor has grown through these layers is the single most important fact in planning treatment.

Almost all bladder cancers in the United States are urothelial carcinomas, which start in the lining cells. They often grow as finger-like papillary tumors that stick out into the bladder, but they can also be flat. A flat, high-grade cancer that stays in the lining is called carcinoma in situ (CIS). CIS can look like a patch of redness, is easy to miss, and behaves aggressively if it is not treated.

Because the same lining covers the kidneys' drainage system (the upper tract), the ureters and the urethra, new tumors can appear anywhere along that path. That is why guidelines ask for imaging of the upper urinary tract at diagnosis and, for some patients, during follow-up. Less common subtypes, called variant histologies, can behave more aggressively and may change the plan.

Tobacco smoking is the most important and most common risk factor. It is estimated to contribute to about half of all bladder cancers. Compared with people who never smoked, the AUA reports that former smokers have about 2.2 times the risk and current smokers about 4.1 times the risk. Quitting lowers the risk over time, although former smokers remain at higher risk than people who never smoked. Secondhand smoke may also raise risk.

Other risk factors named by the guidelines include long-term workplace exposure to certain chemicals (aromatic amines from dye, rubber, paint and petroleum industries, and polycyclic aromatic hydrocarbons), arsenic in drinking water, prior pelvic radiation, certain medicines such as cyclophosphamide and pioglitazone, chronic irritation or infection of the bladder, including schistosomiasis in some parts of the world, and Lynch syndrome. Male sex, older age and white race are also associated with higher rates, while survival is worse overall for African American patients.

Family history appears to play a small role, and the EAU finds no evidence to support genetic screening for bladder cancer. The most useful thing most people can do is stop smoking, and every guideline counsels it.

The most common first sign is painless blood in the urine. It can be visible (pink, red or cola-colored urine, sometimes with clots) or found only on a urine test under a microscope. Visible blood is associated with a higher chance of a more advanced tumor. Blood found only on a urine test is far more often due to something harmless; the AUA notes a cancer rate of roughly 2.6% in people with no symptoms who have microscopic blood. Even so, both deserve a proper evaluation.

Some people, particularly those with carcinoma in situ, notice irritating bladder symptoms without an infection: needing to urinate often, urgency, or burning. Pain in the side or back, swelling of the legs, bone pain or weight loss are less common and usually point to more advanced disease.

If blood in the urine keeps coming back, or bladder symptoms do not settle with treatment for infection, ask whether a urology evaluation is needed.

The key test is cystoscopy, in which a urologist passes a thin camera through the urethra to look inside the bladder. If a tumor is seen, the next step is a transurethral resection of bladder tumor (TURBT), done under anesthesia. The surgeon removes all visible tumor through the urethra and sends it to the pathologist, who reports the grade and how deep it has grown. A good TURBT should include some bladder muscle in the sample whenever the tumor might be high grade, so that invasion is not missed. During the same procedure the surgeon examines the pelvis by hand (an exam under anesthesia).

Guidelines also ask for imaging of the upper urinary tract (the kidneys and ureters), usually a CT urogram, or an MRI urogram if CT contrast cannot be used. A urine test called cytology looks for cancer cells and is good at finding high-grade cancer and CIS. Enhanced cystoscopy with blue light, or narrow-band imaging, can make small or flat tumors easier to see. For muscle-invasive cancer, staging adds a CT of the chest and cross-sectional imaging of the abdomen and pelvis, plus blood tests of kidney and liver function. MRI of the pelvis and FDG-PET/CT may help in selected patients.

For high-grade tumors, especially T1 tumors, a second TURBT within about six weeks is often recommended. Up to half of T1 tumors are found to be more advanced at later surgery, and the repeat resection catches leftover or deeper disease before treatment is chosen. When the pathology shows unusual subtypes, review by an experienced genitourinary pathologist is recommended.

Bladder cancer is staged with the TNM system. T describes how deep the main tumor goes, N whether lymph nodes are involved, and M whether it has spread to distant organs. Ta, Tis (CIS) and T1 together make up non-muscle-invasive disease. T2 and above are muscle-invasive. Clinical stage comes from the TURBT, the exam under anesthesia and imaging; pathologic stage comes from examining the bladder and lymph nodes after cystectomy, and it can be higher than the clinical stage.

Grade describes how abnormal the cells look. Under the World Health Organization system used in the United States, tumors are called low grade or high grade. Low-grade tumors often come back but rarely become life-threatening. High-grade tumors are more likely to grow into the muscle. A very slow-growing lesion called papillary urothelial neoplasm of low malignant potential (PUNLMP) is grouped with low-risk disease. Lymphovascular invasion (cancer cells seen inside small vessels) is reported because it signals a worse outlook.

For non-muscle-invasive cancer, the plan is driven by a risk group (low, intermediate, high, and, in the NCCN and EAU systems, very high). The risk group comes from the stage, grade, size, number of tumors, whether CIS is present, whether it is a first tumor or a recurrence, and how it responded to any earlier treatment. The AUA asks doctors to assign a risk group every time a tumor appears or comes back, because the right next step depends on it.

For muscle-invasive cancer, guidelines ask that all curative options be discussed before a plan is chosen, taking into account both the tumor and the person's overall health. Those options include chemotherapy followed by removal of the bladder, and bladder-preserving treatment that combines a thorough TURBT with chemotherapy and radiation. The AUA recommends a multidisciplinary evaluation, meaning input from a urologist, a medical oncologist and a radiation oncologist. The EAU suggests that high-risk and very high-risk non-muscle-invasive cases also be discussed at a multidisciplinary tumor board when possible.

Shared decision-making matters here because the options affect daily life very differently: urinary control, sexual function, fertility, bowel function, body image and how many procedures you are willing to have. Before treatment, guidelines ask clinicians to talk through these effects openly. Frailty, kidney function and other illnesses also shape which treatments are safe, and the EAU stresses that frailty matters more than age alone.

After a complete TURBT, the next step depends on the risk group. For low-risk and many intermediate-risk tumors, guidelines suggest a single dose of chemotherapy (usually gemcitabine or mitomycin) placed into the bladder within 24 hours of surgery. It lowers the chance of recurrence; NCCN describes about a 35% reduction in five-year recurrence. It is skipped if the bladder wall may have been perforated or the resection was very extensive. Low-risk patients do not need a further course of bladder treatments.

Intermediate-risk patients may be offered a six-week induction course of either chemotherapy or BCG placed into the bladder, sometimes followed by maintenance. High-risk patients are offered BCG, which is the most effective bladder treatment for preventing both recurrence and progression in this group, followed by maintenance for up to three years if it works and is tolerated. Some high-risk features prompt a discussion of removing the bladder early, before the cancer has a chance to invade.

The groups below are not identical across organizations. The AUA has three groups. NCCN uses the AUA groups but flags very high-risk features within the high-risk group. The EAU builds four groups from a scoring model that also counts age over 70, multiple tumors and size over 3 cm, and estimates the chance of progression to muscle invasion at 10 years as under 4% for its low-risk group but about 53% to 59% for its very high-risk group.

BCG (bacillus Calmette-Guérin) is a weakened form of the bacterium used in tuberculosis vaccines. Placed into the bladder through a catheter, it triggers an immune reaction that attacks remaining cancer cells. Induction is usually six weekly instillations starting about three to four weeks after TURBT; the EAU says BCG must not be given in the first two weeks after TURBT, with visible blood in the urine, after a traumatic catheter insertion, or during a symptomatic urinary infection. You hold the medicine in the bladder for a period, then urinate it out.

Maintenance helps BCG work. Many US centers follow the SWOG schedule: after induction, three weekly instillations at 3, 6, 12, 18, 24, 30 and 36 months. Guidelines aim for one year of maintenance in intermediate-risk disease and three years in high-risk disease, as tolerated. In a large European trial, three years of full-dose maintenance lowered recurrence compared with one year in high-risk patients, but not in intermediate-risk patients, and made no difference to progression or survival.

BCG has been in short supply in recent years, with global shortages in 2014 and 2019. The AUA notes that its BCG shortage statement may override parts of the guideline. NCCN lists practical steps used during shortages: give BCG first to high-risk patients (high-grade T1 and CIS), especially for induction and the early maintenance doses at 3 and 6 months; adjust or skip maintenance for intermediate-risk patients; stop high-risk maintenance at one year; split a vial so one-third or one-half doses can treat more patients; and use other bladder treatments when BCG is not available, such as sequential gemcitabine and docetaxel, mitomycin, gemcitabine, epirubicin, valrubicin, docetaxel, or gemcitabine with mitomycin. Reduced doses may be slightly less effective in some trials, which is why they are reserved for shortages.

Doctors use the term BCG-unresponsive when more BCG is unlikely to help. In the EAU definition, which was developed with the US Food and Drug Administration, this means high-grade cancer that is still present or returns within six months of adequate BCG (at least two courses, or induction plus maintenance), or CIS within 12 months. Low-grade recurrences after BCG are not counted as BCG failure. The AUA says further BCG should not be prescribed in this situation, or to people who cannot tolerate BCG.

Radical cystectomy, removal of the bladder, remains the standard and the safest option for cancer control. The AUA recommends offering it to high-risk patients whose cancer persists or returns within a year of two induction courses or BCG maintenance, NCCN lists it as preferred, and the EAU states that other treatments are considered less effective for cancer control in this setting.

For people who cannot have or do not want cystectomy, the guidelines name several bladder-sparing options, each studied mostly in single-group trials. Response rates are lower than with cystectomy and many responses do not last, so close follow-up continues. A clinical trial is encouraged by all three organizations.

When cancer has reached the bladder muscle, there is a real chance that tiny deposits have already escaped beyond the bladder. Cisplatin-based combination chemotherapy given before cystectomy (neoadjuvant chemotherapy) treats those deposits early and improves survival in randomized trials. All three organizations recommend it for people whose kidneys, hearing, nerves, heart and general fitness allow cisplatin. NCCN lists dose-dense MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) for three to six cycles as preferred, with gemcitabine and cisplatin for four cycles as another option.

Carboplatin is not a substitute for cisplatin before surgery. If cisplatin is not safe, guidelines recommend going straight to surgery or bladder-preserving treatment, or joining a clinical trial. After chemotherapy, cystectomy should follow as soon as you have recovered, ideally within 12 weeks. If no chemotherapy is given, the EAU advises against delaying cystectomy more than three months.

After cystectomy, the final pathology guides further treatment. People who did not receive neoadjuvant cisplatin and whose cancer was pT3, pT4 or node-positive may be offered cisplatin-based chemotherapy or the immunotherapy nivolumab. People who did receive it but still had muscle-invasive or node-positive cancer in the specimen may be offered nivolumab, which improved disease-free survival in the CheckMate 274 trial. The EAU rates adjuvant nivolumab as a weak recommendation for selected patients who cannot have or decline cisplatin.

Radical cystectomy removes the bladder together with nearby lymph nodes. In men the prostate and seminal vesicles are usually removed as well. In women the bladder is removed, and nearby reproductive organs may be removed depending on the cancer's location; organ-sparing approaches that keep the uterus, vagina or ovaries can be considered in carefully selected women. Nerve-sparing or sexual-function-preserving techniques may be discussed when the cancer is confined to the bladder and does not involve the bladder neck, urethra or prostate. A bilateral pelvic lymph node dissection is a required part of the operation, removing at least the external iliac, internal iliac and obturator nodes.

The operation can be done through an open incision or with robotic assistance. A randomized trial cited by the AUA found similar rates of complications at 90 days with both approaches. The EAU asks surgeons to explain the pros and cons of each and recommends choosing experienced centers rather than a specific technique, suggesting hospitals perform at least 10, and preferably more than 20, cystectomies a year.

Once the bladder is removed, urine needs a new path. The AUA asks that all three main options be discussed. An ileal conduit uses a short piece of bowel to carry urine to an opening on the belly (a stoma), where it drains into a bag. A continent cutaneous pouch is an internal reservoir that you empty through a small stoma with a catheter several times a day. An orthotopic neobladder is a reservoir made from bowel and connected to the urethra so you urinate through the usual route, which requires a cancer-free urethral margin. The choice depends on cancer location, kidney and bowel function, dexterity, support at home and personal preference. A conduit is the simplest and most common; a neobladder avoids a bag but takes training and may need catheter use, especially in women.

Some people with muscle-invasive cancer want to keep their bladder, and others are not well enough for cystectomy. For them, guidelines support trimodality therapy: a maximal TURBT that removes as much tumor as safely possible, followed by external beam radiation given together with chemotherapy that makes the radiation work better (a radiosensitizer such as cisplatin, low-dose gemcitabine, or 5-FU with mitomycin). NCCN lists this as a category 1 option for cT2 disease.

Not everyone is a good candidate. The best results are seen with a single tumor, ideally smaller than 6 cm, that can be completely or almost completely removed by TURBT, with no blockage of the kidneys (hydronephrosis) and no widespread CIS. No completed randomized trial has compared trimodality therapy directly with cystectomy, and observational studies have conflicting results, so the decision depends on careful selection and a frank discussion. Radiation alone, chemotherapy alone, or TURBT alone are not recommended as cure-intended treatment, and partial cystectomy is reserved for highly selected people with a single tumor in a suitable spot and no CIS.

Keeping the bladder means keeping up with surveillance. Cystoscopy follows the high-risk non-muscle-invasive schedule, along with CT scans and urine cytology. If muscle-invasive cancer remains or returns and you are fit, cystectomy is recommended. If a non-invasive tumor returns, it may be treated with TURBT and bladder instillations, or with cystectomy.

When bladder cancer has spread to distant lymph nodes or organs such as the lungs, liver or bone, treatment focuses on medicines that travel throughout the body. The goals are to control the cancer, relieve symptoms and help people live longer and better. Choices depend on kidney function, overall fitness, earlier treatments and tumor testing. NCCN recommends molecular testing of the tumor, including for FGFR3 alterations and HER2 overexpression, to look for targeted options.

For first-line treatment, NCCN v5.2024 lists pembrolizumab with enfortumab vedotin (an antibody-drug conjugate) as preferred, category 1, whether or not cisplatin can be given. Other recommended options include gemcitabine with cisplatin followed by avelumab maintenance, and nivolumab with gemcitabine and cisplatin followed by nivolumab maintenance; gemcitabine with carboplatin followed by avelumab is an option when cisplatin is not safe. The EAU 2023 guideline, written before the enfortumab and pembrolizumab combination data, still recommends cisplatin-based chemotherapy first with avelumab maintenance for stable or responding disease. This is an area where guidance is changing quickly.

Later lines of treatment may include pembrolizumab or other checkpoint inhibitors after chemotherapy, enfortumab vedotin, erdafitinib for tumors with susceptible FGFR3 alterations, sacituzumab govitecan, trastuzumab deruxtecan for strongly HER2-positive tumors, and other chemotherapy. Radiation or surgery may help control bleeding, blockage or pain. Palliative care can be involved at any point to manage symptoms and support decisions.

TURBT usually causes a few days of blood in the urine and burning, and sometimes a short time with a catheter. A single dose of chemotherapy after TURBT mostly causes temporary bladder irritation. BCG commonly causes burning, frequency and blood in the urine for a day or two after each dose; painful urination was reported in about 60% of patients in trials. Flu-like symptoms lasting 48 to 72 hours are common. These effects are treatable in almost all cases, and the dose can be reduced or delayed. Rarely, BCG causes a serious infection in the body. Fever above 38.5 °C (101.3 °F) for more than 48 hours, or feeling very unwell, needs urgent assessment and stops further BCG.

Radical cystectomy is major surgery. The AUA reports serious complications in about 20% of patients, hospital readmission in 10% to 30%, and death within the recovery period under 3% in most series, higher (4% to 6%) in people over 75. Common problems include a slow-to-wake bowel (ileus), infections and diversion-related issues. Over time, people with a diversion can develop narrowing where the ureters join the bowel, kidney stones, kidney function decline, metabolic acidosis, low vitamin B12 and a higher fracture risk. With a conduit, stoma problems occur in up to about 24% (EAU). With a neobladder, daytime control in men improved from 59% early on to 92% by 12 to 18 months in one study, but nighttime leakage is common, and many women need to use a catheter to empty.

Sexual function is often affected. Even with nerve-sparing techniques, the AUA cites a 40% or greater risk of erection problems in men. Women report loss of desire, orgasm difficulty and painful intercourse, which organ-sparing surgery may reduce. Chemoradiation can cause temporary bladder and bowel irritation in most patients; in one study late bladder and bowel effects affected 27% to 29%, though modern techniques lower the risk of serious late damage to under 5% (EAU). Chemotherapy and immunotherapy have their own effects, from tiredness, nausea, low blood counts and nerve or kidney problems to immune inflammation of organs, and your oncology team will review these before starting.

Bladder cancer follow-up is long because recurrences are common and can appear years later. For non-muscle-invasive disease, the first check cystoscopy is done about three months after treatment in every risk group, since its result is one of the strongest predictors of what comes next. After that, the schedule depends on the risk group. Urine tests do not replace cystoscopy. For intermediate-, high- and very high-risk disease treated without cystectomy, the EAU recommends lifelong follow-up because recurrences after 10 years are not unusual.

After cystectomy, there is no bladder to look into, so follow-up relies on CT or MRI of the chest, abdomen and pelvis, blood tests for kidney and liver function and vitamin B12, and urine tests. Most recurrences after cystectomy happen in the first two to three years. People who keep the urethra are monitored for urethral recurrence. NCCN stresses that no single schedule fits everyone and that follow-up can be adjusted, or extended past five years, through shared decision-making.

Living with a urostomy or neobladder takes adjustment. The AUA recommends detailed teaching on caring for the urinary diversion before you leave the hospital, and recommends meeting an ostomy (enterostomal therapy) nurse before surgery. Practical worries about leaks, odor, clothing or intimacy are common and worth raising.

Sexual health deserves direct attention. Changes in erections, ejaculation, vaginal comfort, desire and body image are common after cystectomy and after pelvic radiation, and guidelines ask clinicians to discuss these and refer to specialists when helpful. Treatments for erection problems, vaginal dilators and lubricants, and counseling can help. Younger patients should ask about fertility preservation before treatment.

The emotional load of frequent cystoscopies and the fear of recurrence is real. The AUA recommends that clinicians ask how patients are coping and suggest support groups or individual counseling. It also encourages healthy habits: stopping smoking, regular exercise and a healthy diet. Quitting smoking matters even after diagnosis, because current tobacco use may be linked to recurrence and progression.

NCCN states that the best management of any patient with cancer is in a clinical trial. Trials are especially important in bladder cancer for people whose disease no longer responds to BCG, who cannot receive cisplatin, or who have advanced disease. Several treatments now approved, such as nadofaragene firadenovec and pembrolizumab for BCG-unresponsive disease, came from such trials. You can ask your team whether a trial fits your situation and search the public registry at ClinicalTrials.gov.

A second opinion is reasonable before a major decision such as cystectomy versus bladder preservation. Guidelines recommend multidisciplinary review for muscle-invasive disease, and the EAU found that tumor board review changed treatment plans in up to 44% of bladder cancer patients, often because of a second look at the pathology. If the pathology shows a variant histology or uncertain muscle invasion, the AUA recommends review by an experienced genitourinary pathologist.

Most side effects are expected and manageable, but some need a prompt call. Your team would rather hear from you early than late. If you feel severely unwell, have chest pain or trouble breathing, go to the nearest emergency department.